These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28635613)

  • 1. Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Treeprasertsuk S; Tanwandee T; Charatcharoenwitthaya P; Thongsawat S; Leerapun A; Piratvisuth T; Boonsirichan R; Bunchorntavakul C; Pattanasirigool C; Pornthisarn B; Tuntipanichteerakul S; Sripariwuth E; Jeamsripong W; Sanpajit T; Poovorawan Y; Komolmit P
    Antivir Ther; 2018; 23(1):67-75. PubMed ID: 28635613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Hu HH; Liu J; Lin YL; Luo WS; Chu YJ; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; You SL; Yang HI; Chen CJ;
    Gut; 2016 Sep; 65(9):1514-21. PubMed ID: 26642861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of S267F variant of NTCP on the patients with chronic hepatitis B.
    Lee HW; Park HJ; Jin B; Dezhbord M; Kim DY; Han KH; Ryu WS; Kim S; Ahn SH
    Sci Rep; 2017 Dec; 7(1):17634. PubMed ID: 29247233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTCP S267F variant associates with decreased susceptibility to HBV and HDV infection and decelerated progression of related liver diseases.
    Binh MT; Hoan NX; Van Tong H; Sy BT; Trung NT; Bock CT; Toan NL; Song LH; Bang MH; Meyer CG; Kremsner PG; Velavan TP
    Int J Infect Dis; 2019 Mar; 80():147-152. PubMed ID: 30685591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Treeprasertsuk S; Tanwandee T; Charatcharoenwitthaya P; Thongsawat S; Leerapun A; Piratvisuth T; Boonsirichan R; Bunchorntavakul C; Pattanasirigool C; Pornthisarn B; Tuntipanichteerakul S; Sripariwuth E; Jeamsripong W; Sanpajit T; Poovorawan Y; Komolmit P
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1257-1264. PubMed ID: 31030503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Loss-of-Function S267F Variant in HBV Receptor NTCP Reduces Human Risk for HBV Infection and Disease Progression.
    An P; Zeng Z; Winkler CA
    J Infect Dis; 2018 Sep; 218(9):1404-1410. PubMed ID: 29905807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
    Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p.Ser267Phe variant of sodium taurocholate cotransporting polypeptide (NTCP) supports HBV infection with a low efficiency.
    Liu C; Xu G; Gao Z; Zhou Z; Guo G; Li D; Jing Z; Sui J; Li W
    Virology; 2018 Sep; 522():168-176. PubMed ID: 30032030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse Effects of the NTCP p.Ser267Phe Variant on Disease Progression During Chronic HBV Infection and on HBV preS1 Variability.
    Yang F; Wu L; Xu W; Liu Y; Zhen L; Ning G; Song J; Jiao Q; Zheng Y; Chen T; Xie C; Peng L
    Front Cell Infect Microbiol; 2019; 9():18. PubMed ID: 30881922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
    Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of NTCP polymorphisms with clinical outcome of hepatitis B infection in Thai individuals.
    Chuaypen N; Tuyapala N; Pinjaroen N; Payungporn S; Tangkijvanich P
    BMC Med Genet; 2019 May; 20(1):87. PubMed ID: 31117968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B.
    Limothai U; Chuaypen N; Khlaiphuengsin A; Chittmittraprap S; Poovorawan Y; Tangkijvanich P
    Antivir Ther; 2017; 22(8):681-688. PubMed ID: 28291736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.